<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Antiparkinson Drugs Pharmacology</title>
  <link rel="stylesheet" href="style.css">
</head>
<body>
 <!-- Header -->
  <header class="site-header">
    <div class="container">
      <div class="logo">
        <a href="index.html">Dr M Medical Courses</a>
      </div>
      <nav class="main-nav">
        <ul>
          <li><a href="index.html">Home</a></li>
          <li><a href="orthopedics.html">Orthopedics Courses</a></li>
          <li><a href="pharmacology.html">Pharmacology Courses</a></li>
          <li><a href="about.html">About</a></li>
        </ul>
      </nav>
    </div>
  </header>
  <header>
    <h1>Antiparkinson Drugs Pharmacology: Levodopa, Carbidopa, Entacapone, Selegiline, Pramipexole & More</h1>
  </header>

  <main>
    <section id="definition">
      <h2>Definition</h2>
      <p>Drugs that work to increase the dopamine levels in the nigrostriatal pathway in the brain to relieve Parkinson’s symptoms.</p>
      <p>They include a lot of drugs, the most famous one being Levodopa.</p>
      <p>To understand antiparkinson’s drugs, first we need to understand Parkinson’s disease.</p>
    </section>

    <section id="parkinsons-disease">
      <h2>Parkinson’s Disease</h2>
      <p>Chronic degenerative disease of the CNS affecting the dopaminergic neurons in the substantia nigra.</p>
      <p>Leading to motor and non-motor symptoms.</p>
      <p>Average age of onset is 60 years old, and it occurs more commonly in males.</p>
    </section>

    <section id="motor-symptoms">
      <h2>Parkinson’s Motor System Symptoms</h2>
      <ul>
        <li>Resting tremor</li>
        <li>Bradykinesia: slowness and inability to initiate movements</li>
        <li>Shuffling gait</li>
        <li>Stooped posture</li>
        <li>Cogwheel rigidity</li>
      </ul>
    </section>

    <section id="non-motor-symptoms">
      <h2>Parkinson’s Non-Motor Symptoms</h2>
      <ul>
        <li>Cognitive impairment and personality changes</li>
        <li>Sleep disorders</li>
        <li>Mood disturbance</li>
        <li>Sensory and autonomic disorders</li>
        <li>Pain</li>
      </ul>
    </section>

    <section id="pathophysiology">
      <h2>Parkinson’s Pathophysiology</h2>
      <p>Loss of dopaminergic neurons in the nigrostriatal pathway (of the substantia nigra) resulting in imbalance of dopaminergic (inhibitory) and cholinergic (excitatory) influences on the extrapyramidal system leading to Parkinson’s.</p>
      <p>Exact cause of the loss of dopaminergic neurons is not fully understood, but there are risk factors.</p>
    </section>

    <section id="risk-factors">
      <h2>Parkinson’s Risk Factors</h2>
      <ul>
        <li>Age above 60 years old</li>
        <li>Male gender</li>
        <li>Genetics</li>
        <li>Oxidative stress</li>
        <li>Family history</li>
        <li>Head trauma</li>
      </ul>
    </section>

    <section id="treatment">
      <h2>Parkinson’s Treatment</h2>
      <p>To treat Parkinson’s, you have to increase dopaminergic activity in the substantia nigra by giving the patient L-dopa and other medications that increase dopaminergic activity.</p>
      <p>Dopamine is available in many locations in the brain, and there is no dopamine medication that is selective for the substantia nigra only, which is why there may be many adverse effects.</p>
      <p>To understand that, you have to learn the dopaminergic pathways in the brain.</p>
    </section>

    <section id="dopaminergic-pathways">
      <h2>Dopaminergic Pathways</h2>
      <p>There are 4 major dopamine pathways in the brain:</p>
      <ol>
        <li>Nigrostriatal pathway</li>
        <li>Mesolimbic pathway</li>
        <li>Mesocortical pathway</li>
        <li>Tuberoinfundibular pathway</li>
      </ol>
    </section>

    <section id="nigrostriatal">
      <h3>Nigrostriatal Pathway</h3>
      <p>Transmits dopamine from substantia nigra to the caudate nucleus and putamen (parts of basal ganglia).</p>
      <p>Related to motor functions, reward-related cognition, and associative learning. Loss of dopaminergic neurons here leads to Parkinson’s disease.</p>
      <p>Antiparkinson’s drugs work to increase dopamine in this pathway to relieve symptoms.</p>
    </section>

    <section id="mesolimbic">
      <h3>Mesolimbic Pathway</h3>
      <p>Transmits dopamine from ventral tegmental area in the midbrain to the ventral striatum (nucleus accumbens and olfactory bulb).</p>
      <p>Functions: reward cognition (pleasure response) and aversion cognition (dislike).</p>
      <p>Increasing dopamine here can lead to psychosis (hallucinations, delusions). Antiparkinson’s drugs also increase dopamine in this pathway.</p>
    </section>

    <section id="mesocortical">
      <h3>Mesocortical Pathway</h3>
      <p>Transmits dopamine from ventral tegmental area to the frontal cortex.</p>
      <p>Related to executive functions. Increasing dopamine here can lead to schizophrenia. Antiparkinson’s drugs also increase dopamine in this pathway.</p>
    </section>

    <section id="tuberoinfundibular">
      <h3>Tuberoinfundibular Pathway</h3>
      <p>Transmits dopamine from hypothalamus to pituitary gland.</p>
      <p>Function: regulate prolactin secretion. This pathway is barely affected by antiparkinson drugs.</p>
    </section>

    <section id="dopamine-other-locations">
      <h2>Dopamine Also Available In</h2>
      <p>Dopamine is also present in the chemoreceptor trigger zone; high levels here lead to nausea and vomiting. Antiparkinson’s drugs increase dopamine in this area.</p>
    </section>

    <section id="classification">
      <h2>Classification of Antiparkinson Drugs</h2>
      <ul>
        <li>Dopaminergic drugs
          <ul>
            <li>Dopamine precursors: levodopa (L-dopa)</li>
            <li>COMT inhibitors: tolcapone, entacapone</li>
            <li>Selective MAO-B inhibitors: selegiline</li>
            <li>Dopamine agonists: bromocriptine</li>
            <li>Release of dopamine and inhibition of its reuptake: amantadine</li>
          </ul>
        </li>
        <li>Anticholinergic drugs: benztropine, orphenadrine, trihexyphenidyl</li>
      </ul>
    </section>

    <section id="levodopa">
      <h2>Levodopa</h2>
      <h3>Pharmacokinetics</h3>
      <p>Good absorption but heavily affected by food; better taken before meals. Short half-life of 1-2 hours can produce on/off phenomenon (sudden tremors and dyskinesia after short recovery).</p>

      <h3>Mechanism of Action</h3>
      <p>Dopamine can’t cross BBB but L-dopa can, which is why L-dopa is used. More than 95% of administered L-dopa is decarboxylated peripherally into dopamine; only <5% crosses BBB. Peripheral decarboxylation can be minimized using a peripheral decarboxylase inhibitor (e.g., carbidopa).</p>
      <p>L-dopa is always used with a decarboxylase inhibitor, increasing CNS availability and reducing adverse effects. Example: Sinemet (L-dopa + carbidopa).</p>
      <p>Dopamine in CNS is metabolized by MAO and COMT.</p>

      <h3>Adverse Effects</h3>
      <ul>
        <li>GIT: nausea and vomiting in 80% of patients. Domperidone can treat vomiting as it doesn’t cross BBB.</li>
        <li>CNS:
          <ul>
            <li>On/off phenomenon: rapid fluctuations in clinical state; solved by COMT inhibitors</li>
            <li>Dyskinesia after long-term use; treated with amantadine or clozapine</li>
            <li>Mood changes, hallucinations, nightmares, anxiety, depression, euphoria</li>
            <li>Antipsychotics with low D2 receptor affinity (e.g., clozapine, olanzapine) may be used</li>
          </ul>
        </li>
        <li>Cardiovascular: arrhythmias, tachycardia, postural hypotension, possible hypertension at high doses</li>
        <li>Other: brownish body secretions, red urine, mydriasis (may precipitate glaucoma)</li>
      </ul>

      <h3>Drug Holiday</h3>
      <p>Discontinuation for 3-21 days to improve responsiveness. Carries risks: aspiration pneumonia, venous thrombosis, pulmonary embolism, depression.</p>

      <h3>Interactions</h3>
      <ul>
        <li>Food: leucine and isoleucine compete with absorption</li>
        <li>Pyridoxine (Vitamin B6) enhances peripheral decarboxylation, reducing CNS L-dopa</li>
      </ul>

      <h3>Contraindications</h3>
      <ul>
        <li>Psychosis and schizophrenia</li>
        <li>Closed-angle glaucoma (open-angle allowed if IOP controlled)</li>
        <li>History of melanoma</li>
      </ul>
    </section>

    <section id="comt-inhibitors">
      <h2>Tolcapone & Entacapone</h2>
      <p>COMT inhibitors block peripheral metabolism of L-dopa, prolonging its CNS action.</p>
      <p>Half-life ~2 hours. Adverse effects similar to L-dopa; Tolcapone may increase liver enzymes and cause hepatic failure, requiring LFT monitoring. Example combination: Stalevo (L-dopa + carbidopa + entacapone).</p>
    </section>

    <section id="mao-inhibitors">
      <h2>Selegiline, Rasagiline & Safinamide</h2>
      <p>Selective MAO-B inhibitors; prolong CNS dopamine, reduce L-dopa dose, decrease on/off phenomenon. Minor effects when alone; always combined with L-dopa. Rosagiline more potent.</p>
      <p><strong>Contraindications:</strong> risk of serotonin syndrome with meperidine, tramadol, methadone, propoxyphene, cyclobenzaprine, St. John's wort, dextromethorphan, TCA antidepressants.</p>
    </section>

    <section id="dopamine-agonists">
      <h2>Pramipexole & Ropinirole</h2>
      <p>Dopamine D2 receptor agonists; directly work on dopamine receptors. Cross BBB without enzymatic conversion. Older agonists (bromocriptine, pergolide) rarely used due to more side effects.</p>
      <p>First-line for Parkinson’s due to lower side effects, less dyskinesia, and less response fluctuations. Used alone or with L-dopa when end-of-dose akinesia occurs. Pramipexole: D3 selective; Ropinirole: pure D2 agonist.</p>

      <h3>Adverse Effects</h3>
      <ul>
        <li>GIT: nausea, vomiting, constipation, dyspepsia, reflux, bleeding</li>
        <li>CVS: postural hypotension, painless digital vasospasm, arrhythmias</li>
        <li>CNS: dyskinesia, confusion, hallucinations, delusions, psychiatric complications</li>
      </ul>

      <h3>Contraindications</h3>
      <ul>
        <li>Psychotic illness</li>
        <li>Recent MI</li>
        <li>Active peptic ulcer</li>
        <li>Bromocriptine: peripheral vascular disease</li>
      </ul>
    </section>

    <section id="amantadine">
      <h2>Amantadine</h2>
      <p>Antiviral drug with mild antiparkinson effects. Plasma half-life ~3 hours, excreted in urine. Less effective than L-dopa; benefits last few weeks. Adverse effects: restlessness, depression, insomnia, agitation, hallucinations, acute psychosis, nausea, vomiting, postural hypotension, urinary retention, increased seizure risk, livedo reticularis (resolves after 1 month).</p>
    </section>

    <section id="anticholinergics">
      <h2>Benztropine, Orphenadrine, Trihexyphenidyl</h2>
      <p>Centrally acting anticholinergics, selective for central muscarinic receptors. Improve tremor, rigidity, and partially bradykinesia. Control drug-induced extrapyramidal side effects.</p>
      <p>Contraindications: prostatic hypertrophy, obstructive GI disease, narrow-angle glaucoma. May worsen dementia in Parkinson’s patients.</p>
    </section>

    <section id="non-motor-therapy">
      <h2>Therapy for Non-Motor Symptoms</h2>
      <ul>
        <li>Cognitive decline: Rivastigmine, Memantine, Donepezil</li>
        <li>Psychosis: atypical antipsychotics</li>
        <li>Excessive sleeping: Modafinil</li>
        <li>Other: symptomatic treatment</li>
      </ul>
    </section>

  </main>

  <footer>
    <p>&copy; 2025 Dr M. All Rights Reserved.</p>
  </footer>

</body>
</html>
